Behavioral Health

Neuroleptic malignant syndrome: recognition and management

Clinical Overview and When to Suspect NMS

— High-potency typical antipsychotics (haloperidol, fluphenazine) — classic offenders

— Atypicals (risperidone, olanzapine, clozapine, aripiprazole) — lower risk but well documented

— Antiemetics with D2 activity: metoclopramide, prochlorperazine, promethazine

— Abrupt withdrawal of dopaminergic therapy in Parkinson disease (levodopa, amantadine) → "parkinsonism-hyperpyrexia syndrome," clinically identical to NMS

— Young male adults, dehydration, agitation, restraints, depot/IM injections, rapid dose escalation, prior NMS episode, catatonia, iron deficiency

Neuroleptic malignant syndrome (NMS) is a life-threatening idiosyncratic reaction to dopamine D2 receptor blockade, characterized by the tetrad of fever, rigidity, autonomic instability, and altered mental status.

Pathophysiology centers on abrupt central dopamine antagonism in the nigrostriatal and hypothalamic pathways, producing rigidity, hyperthermia, and dysautonomia, plus peripheral skeletal muscle hypermetabolism → rhabdomyolysis.

Triggers:

Risk factors:

Onset is typically subacute over 24–72 hours, but can occur anytime from hours after first dose to weeks into therapy; >90% occur within 10 days of initiation or dose change.

Mortality 5–20% if untreated, mainly from rhabdomyolysis/AKI, aspiration pneumonia, PE, DIC, arrhythmia.

Step 3 management: In any ED patient on antipsychotics or antiemetics presenting with fever + altered mental status, stop the offending agent immediately while completing the workup — do not wait for confirmatory labs. Document the medication reconciliation explicitly.

Board pearl: A Parkinson disease patient admitted for elective surgery whose carbidopa-levodopa is held NPO and who then develops fever and rigidity has NMS-equivalent parkinsonism-hyperpyrexia syndrome — treat by restarting dopaminergic therapy (NG tube if needed), not by adding a new agent.

Presentation Patterns and Key History

— Mental status change first (confusion, mutism, catatonia-like stupor)

— Then "lead-pipe" rigidity (sustained, not cogwheel)

— Then hyperthermia (often >38.5°C, can exceed 41°C)

— Then autonomic instability (labile BP, tachycardia, diaphoresis, tachypnea)

— Any antipsychotic started, increased, or switched in last 1–4 weeks

— Recent depot injection (haloperidol decanoate, paliperidone) — risk persists for weeks

— Antiemetic exposure in postop, gastroparesis, migraine, or chemo patients (metoclopramide is the most-missed culprit on boards)

— Parkinson disease meds held (NPO status, malabsorption, deliberate "drug holiday")

— Prior NMS, prior catatonia, recent ECT

— Dehydration, heat exposure, physical restraints, agitation

— Psychiatric inpatient on haloperidol PRN for agitation → 48 h later: fever, rigid, mute

— Postop patient given IV metoclopramide for nausea → confusion + rigidity

— Parkinson patient post-bowel-prep → tremor worsens to rigidity, fever spikes

— Outpatient started on risperidone for behavioral dementia → subacute decline

Classic tetrad evolves in a stereotyped sequence in ~70% of cases:

Key historical anchors to elicit in the ED:

Common clinical phenotypes tested:

Key distinction: NMS rigidity is symmetric, generalized "lead-pipe" rigidity without clonus; serotonin syndrome shows hyperreflexia, clonus (especially lower extremity), and tremor; malignant hyperthermia presents intraoperatively during volatile anesthetics or succinylcholine.

Board pearl: Ask explicitly about all medications in the last 30 days including PRNs, depot injections, and antiemetics — the offending drug is often given for nausea or sleep, not psychosis, and is easily missed on the standard med list reviewed at triage.

Physical Exam Findings and Hemodynamic Assessment

— Hyperthermia (>38°C in virtually all; often 39–41°C)

— Tachycardia, tachypnea, labile blood pressure (swings between hypertension and hypotension within hours)

— Profuse diaphoresis despite high temperature

— Generalized lead-pipe rigidity — passive movement feels uniformly resistant ("plastic")

— Bradykinesia, dysphagia, sialorrhea, dysarthria

— Altered sensorium: ranges from agitated delirium → mutism → stupor → coma

— Tremor (coarse, low frequency) may be present but is not dominant

— Reflexes typically normal or decreased, NOT hyperreflexic

— No clonus, no mydriasis

— Urinary incontinence or retention common

— Tea-colored urine from myoglobinuria

— Decreased bowel sounds (autonomic ileus)

— Aspiration risk from dysphagia/mutism

— NMS: rigidity > hyperthermia, hyporeflexia, no clonus

— Serotonin syndrome: clonus, hyperreflexia, mydriasis, GI hyperactivity (diarrhea, bowel sounds)

— Anticholinergic toxicity: dry skin, mydriasis, urinary retention, no rigidity ("dry as a bone")

— Malignant hyperthermia: occurs in the OR, masseter spasm, ETCO₂ rises early

Vital signs:

Neurologic exam:

Skin: hot, diaphoretic, pallor, sometimes mottled

Other:

Hemodynamic pattern is hyperdynamic dysautonomia: high HR, high cardiac output, but BP swings due to autonomic dysregulation rather than fixed shock. Watch for late hypotension signaling decompensation, rhabdo-AKI volume depletion, or PE.

Key distinction (exam-based):

CCS pearl: On initial ED orders include continuous telemetry, core temperature monitoring (rectal or bladder probe — axillary underestimates), Foley with strict I/Os, and pulse oximetry — autonomic instability and aspiration risk demand close monitoring well before ICU transfer is finalized.

Diagnostic Workup — Initial Labs

— CBC — leukocytosis (often 10–40 k) with left shift is typical

— CMP — AKI from rhabdo, hyperkalemia, hyperphosphatemia, hypocalcemia, transaminitis (AST often > ALT)

— CPK (creatine kinase) — markedly elevated, often >1,000 U/L and frequently >10,000; degree correlates with severity and AKI risk

— Urinalysis with myoglobin — dipstick heme-positive without RBCs = myoglobinuria

— LDH, uric acid, lactate — elevated from muscle breakdown

— Coagulation panel (PT/PTT, fibrinogen, D-dimer) — screen for DIC

— Iron studies — low serum iron is a sensitive (though nonspecific) marker

— ABG/VBG — metabolic acidosis (lactic + from rhabdo)

— Blood cultures, urine culture, CXR — sepsis is the #1 mimic; obtain before or with empiric coverage

— Acetaminophen, salicylate, ethanol, urine drug screen — exclude toxidromes

— TSH — thyroid storm in differential

— ECG — sinus tachycardia, screen for QT prolongation (relevant before any antipsychotic re-exposure)

— CXR — aspiration pneumonia, pulmonary edema

— CT head non-contrast if focal deficits, trauma, or to exclude intracranial cause of altered mental status

NMS is a clinical diagnosis; labs support it and rule out mimics.

Order on arrival:

Imaging:

Board pearl: Three labs that nail NMS on the exam are elevated CK, leukocytosis, and low serum iron, alongside the clinical tetrad — but no single lab is diagnostic; CK can be only mildly elevated early.

Step 3 management: Send a lactate and venous pH within 30 min — acidosis and lactate >4 are decompensation markers that push you toward ICU disposition rather than monitored bed, and they guide aggressive fluid resuscitation targets for rhabdomyolysis prevention.

Diagnostic Workup — Advanced and Confirmatory Studies

— Major (need both): exposure to dopamine antagonist (or DA agonist withdrawal) + hyperthermia + rigidity

— Minor: altered mental status, autonomic instability (≥2 of: BP changes, diaphoresis, dysphagia, tremor, incontinence, leukocytosis, elevated CK), tachycardia, tachypnea

— Lumbar puncture if meningitis/encephalitis cannot be excluded — CSF in NMS is typically normal or mildly elevated protein; sterile

— EEG if persistent encephalopathy or to exclude nonconvulsive status epilepticus — usually shows diffuse slowing, no epileptiform discharges

— MRI brain if focal signs or prior to attributing coma to NMS alone

— Echocardiogram if persistent hypotension or troponin elevation — stress cardiomyopathy can complicate severe NMS

— CT chest / CTA-PE if hypoxia or unexplained tachycardia — PE is a leading cause of death due to immobility + dehydration + hypercoagulability

— Toxicology consult if mixed exposures or unclear toxidrome

— Neurology consult for catatonia overlap, Parkinson-hyperpyrexia, or atypical features

— Psychiatry consult for medication reconciliation and to plan future antipsychotic strategy

No confirmatory test exists; diagnosis uses DSM-5/Levenson criteria:

When the picture is atypical, escalate workup to exclude mimics:

Specialty input:

Document a medication timeline with dates, doses, routes — this is the single most exam-relevant data point and is required for safe re-challenge planning later.

Key distinction: Lethal catatonia can be clinically indistinguishable from NMS but precedes antipsychotic exposure — preceded by weeks of psychotic excitement, posturing, and stereotypies. Treatment overlap with benzodiazepines and ECT, but antipsychotics worsen lethal catatonia — be careful before re-dosing.

CCS pearl: Repeat CK every 6–12 h until trending down; rising CK after 24 h of treatment signals ongoing muscle injury and inadequate cooling/sedation — this is a CCS-style trigger to escalate to ICU and add benzodiazepine or dantrolene.

Risk Stratification and First-Line Management Logic

— Mild: rigidity + temp <38°C + HR <100, normal mentation

— Moderate: rigidity + temp 38–40°C + HR 100–120 + mild confusion

— Severe: temp >40°C, marked autonomic instability, stupor/coma, CK >10× ULN, AKI

— Stop the offending agent immediately — antipsychotics, antiemetics, lithium, anticholinergics that may worsen hyperthermia

— Restart dopaminergic therapy if cause is PD-med withdrawal — give levodopa via NG if NPO

— ABC + IV access × 2, continuous monitoring

— Aggressive IV fluid resuscitation with isotonic crystalloid; target urine output >1–2 mL/kg/h to prevent myoglobin-induced AKI

— Active cooling if T >39.5°C — evaporative cooling, ice packs to groin/axillae, cooling blankets; avoid antipyretics (acetaminophen/NSAIDs ineffective — this is not prostaglandin-mediated fever)

— Benzodiazepines (lorazepam 1–2 mg IV q4–6h) — first-line for agitation/rigidity in mild–moderate cases; also covers catatonia overlap

— Correct electrolytes: K⁺, Ca²⁺, PO₄, Mg; treat hyperkalemia aggressively

— DVT prophylaxis as soon as bleeding excluded — immobility + dehydration = high PE risk

— Mild → monitored bed/step-down, IVF, lorazepam, serial CK

— Moderate–severe → ICU, add dantrolene/bromocriptine, consider intubation

— Refractory >48 h → consider ECT

Severity grading (Woodbury / clinical):

Universal first steps (do simultaneously, not sequentially):

Disposition logic:

Step 3 management: The single most important order is discontinuation of the dopamine antagonist — failure to do so is the most common error tested. Write it explicitly in the orders and flag it in the allergy/adverse-reaction list so it propagates across transitions of care.

Board pearl: Antipyretics don't work in NMS — hyperthermia is from peripheral muscle hypermetabolism, not central thermoregulatory set-point change. Cool physically.

Pharmacotherapy — First-Line Drug Regimen

— Lorazepam 1–2 mg IV q4–6h (or diazepam 5–10 mg IV)

— Reduces agitation, rigidity, autonomic tone; treats overlapping catatonia

— Watch for respiratory depression — have airway ready

— Mechanism: blocks ryanodine receptor → inhibits Ca²⁺ release from sarcoplasmic reticulum → reduces muscle hypermetabolism

— Dose: 1–2.5 mg/kg IV q6h, max 10 mg/kg/day; transition to PO 50–100 mg QID once improving

— Continue 24–48 h after symptom resolution, then taper over 7–10 days to avoid rebound

— Hepatotoxic — monitor LFTs; avoid in significant liver disease

— Restores central dopamine tone

— Dose: 2.5 mg PO/NG q6–8h, titrate up to 40 mg/day

— Continue 10–14 days then taper; abrupt stop can precipitate recurrence

— Side effects: hypotension, nausea, psychosis exacerbation

— Antipyretics — ineffective

— Anticholinergics (benztropine, diphenhydramine) — impair sweating, worsen hyperthermia

— Bromocriptine in serotonin syndrome patients — opposite mechanism

— Reintroduction of any D2 blocker until full recovery + 2 weeks

Benzodiazepines (first-line in mild–moderate disease):

Dantrolene (moderate–severe, especially with extreme hyperthermia, rigidity, rhabdo):

Bromocriptine (dopamine D2 agonist, oral/NG):

Amantadine alternative (100–200 mg PO BID) if bromocriptine unavailable.

Avoid:

Key distinction: Dantrolene is also first-line for malignant hyperthermia, but in MH it is the primary therapy started in the OR; in NMS it is reserved for moderate–severe disease alongside drug discontinuation, cooling, and IVF.

Step 3 management: Combination therapy (benzodiazepine + dantrolene + bromocriptine) is reasonable in severe/refractory NMS, but document the rationale — RCT evidence is limited, and overlapping side-effect profiles (hypotension, sedation, hepatotoxicity) require monitored care.

Refractory Disease and Advanced Management

— Indicated for refractory NMS, lethal catatonia overlap, or when re-initiation of antipsychotics is impossible

— Typical course: 6–10 bilateral sessions, often daily initially

— Response usually within first 3–4 treatments

— Pre-ECT: ensure dantrolene has been held ≥24 h (interaction with anesthesia variable), correct electrolytes, exclude raised ICP

— Anesthesia caution: avoid succinylcholine if CK very high or hyperkalemic — use rocuronium

— Intubation and mechanical ventilation for airway protection (mutism, dysphagia, aspiration), hyperthermia control with neuromuscular blockade

— Neuromuscular paralysis (vecuronium/rocuronium) — abolishes rigidity, drops temperature, reduces CK production; sedate concurrently

— CRRT/hemodialysis for AKI with refractory hyperkalemia, severe acidosis, or volume overload

— Vasopressors for refractory hypotension — norepinephrine first; avoid dopamine if possible (mechanistically counterintuitive but also arrhythmogenic in dysautonomia)

— DVT/PE prophylaxis with LMWH once safe; mechanical compression in the interim

— Hyperkalemia → calcium, insulin/dextrose, dialysis

— Hypocalcemia (from PO₄ binding) → replace only if symptomatic to avoid metastatic calcification during recovery phase

— Hyperthermia >41°C → paralysis + cooling, target <38.5°C within 1 h

Definition of refractory NMS: persistent hyperthermia, rigidity, or autonomic instability >48 h despite drug discontinuation, IVF, cooling, benzodiazepines, dantrolene, and bromocriptine.

Electroconvulsive therapy (ECT):

Supportive ICU care:

Targeted complications:

CCS pearl: Once stabilized, stop dantrolene gradually over 7–10 days and continue bromocriptine for 2 weeks; premature discontinuation is a classic CCS pitfall leading to rebound NMS within 24–72 hours.

Board pearl: In an exam stem with NMS unresponsive to dantrolene + bromocriptine at 72 h, the next step is ECT, not adding a third pharmacologic agent.

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher risk due to polypharmacy, dehydration, dementia behavioral agents (risperidone, quetiapine, haloperidol), and use of antiemetics for nausea/vertigo

— Presentation often atypical: less prominent fever, dominant delirium and rigidity; easily misattributed to UTI/sepsis or dementia decompensation

— Mortality higher; lower threshold for ICU

— Dose adjustments:

– Lorazepam: start 0.25–0.5 mg IV — risk of delirium and falls

– Dantrolene: standard weight-based dose but follow LFTs closely

– Bromocriptine: start 1.25 mg q8h, titrate slowly — orthostatic hypotension and confusion common

— Avoid restarting any D2 antagonist; if antipsychotic absolutely needed long-term, use quetiapine or clozapine (lower D2 affinity) after ≥2 weeks recovery, with low-dose, slow titration

— Fluid resuscitation remains cornerstone, but watch for volume overload once oliguric

— Avoid NSAIDs

— Bromocriptine and amantadine are renally cleared — reduce amantadine dose (CrCl 30–50: 100 mg daily; <30: 100 mg q2–3 days)

— Consider early CRRT for severe rhabdo + AKI + hyperkalemia

— Dantrolene contraindicated with active liver disease or transaminases >5× ULN; choose bromocriptine + benzodiazepines + ECT instead

— Lorazepam preferred over diazepam/midazolam in cirrhosis (no active metabolites, glucuronidation only)

Elderly:

Renal impairment / AKI from rhabdomyolysis:

Hepatic impairment:

Key distinction: In an elderly nursing-home resident on metoclopramide for gastroparesis who develops "delirium with stiffness," NMS is the diagnosis until proven otherwise — sepsis workup is parallel, not sequential.

Step 3 management: Update the medication list and pharmacy record with the offending drug as a documented adverse reaction before discharge or transfer — this prevents re-exposure across facility transitions, a high-yield Step 3 patient-safety theme.

Special Populations — Pregnancy and Pediatrics

— NMS can occur with antipsychotics used for psychosis, hyperemesis (metoclopramide, prochlorperazine, promethazine), or peripartum mood disorders

— Maternal hyperthermia >39°C is teratogenic in 1st trimester and causes fetal distress later; aggressive cooling is essential

— Treatment priorities:

– Stop offending drug; aggressive IVF and cooling

– Benzodiazepines safe in acute setting despite category D — risk/benefit favors use

– Dantrolene: limited pregnancy data; used in obstetric MH, considered acceptable in severe NMS

– Bromocriptine: historically used for lactation suppression; can be used acutely but suppresses lactation and rarely causes stroke/MI postpartum — limit duration

– ECT is safe in pregnancy with fetal monitoring and is preferred for refractory cases

— Fetal monitoring (continuous after viability), OB consult, NICU notification if delivery imminent

— Increasing incidence with off-label antipsychotic use for autism-related agitation, tics, behavioral dysregulation

— Often atypical: more dystonia and catatonia features, less classic rigidity

— Antiemetics (metoclopramide, promethazine — contraindicated <2 yrs) are common triggers

— Dosing: lorazepam 0.05–0.1 mg/kg IV; dantrolene 1–2.5 mg/kg IV q6h; bromocriptine pediatric data sparse

— Higher proportion of cases linked to abrupt antipsychotic discontinuation/switches in adolescents

— If patient breastfeeding, bromocriptine will suppress lactation — discuss alternatives or pumping/discarding

Pregnancy:

Pediatrics and adolescents:

Postpartum / lactation:

Board pearl: ECT is the safest definitive therapy in pregnant NMS when pharmacologic options are limited — exam-favorite for refractory peripartum cases.

CCS pearl: In any pregnant patient with fever + altered mental status on neuroleptics, order continuous fetal monitoring, OB consult, and core temperature management in the initial order set — these are scored items on obstetric-flavored CCS cases.

Complications and Adverse Outcomes

— CK often >10,000–100,000 U/L

— Myoglobinuric AKI in ~30%; preventable with early aggressive crystalloid (goal UO 1–3 mL/kg/h)

— Hyperkalemia → arrhythmia is a leading early killer

— Chest wall rigidity, dysphagia, sialorrhea → aspiration pneumonia (most common infectious complication)

— Hypoventilation from sedation, PE

— Low threshold for intubation if RR >30, hypoxia, or GCS declining

— Arrhythmias from electrolyte derangements and autonomic storm

— Stress (takotsubo) cardiomyopathy, MI from supply-demand mismatch

— Hypotension may signal sepsis, PE, or DIC

— DVT/PE due to dehydration, immobility, hypercoagulability — major mortality driver

— Start chemoprophylaxis as soon as bleeding risk acceptable

— Persistent parkinsonism, cerebellar ataxia, cognitive impairment in <5%

— Usually full neurologic recovery within 2–4 weeks

— Rate 15–30% with re-challenge; lower if waited ≥2 weeks and used lower-potency, lower-D2-affinity agent (quetiapine, clozapine)

Rhabdomyolysis and acute kidney injury:

Respiratory failure:

Cardiovascular:

Thromboembolism:

DIC: from tissue injury, hyperthermia; correlates with worse prognosis

Hepatic dysfunction: transaminitis from muscle and hepatocellular injury; dantrolene can compound

Neurologic sequelae:

Recurrence:

Key distinction: Persistent fever after rigidity resolves should prompt search for secondary infection (aspiration pneumonia, line sepsis, UTI) or PE, not "ongoing NMS." Re-image and re-culture rather than escalating NMS-directed therapy.

Step 3 management: Daily monitoring bundle: CK trend, BUN/Cr, K⁺, LFTs, CBC, coags, UO; document trajectory and explicit reassessment of need for restraints, sedation, and lines — these become Joint Commission-flagged issues if not justified.

When to Escalate Care — ICU, Consult, and Triage

— Temperature >40°C or rising despite cooling

— Hemodynamic instability (MAP <65, refractory tachycardia, vasopressor need)

— CK >5,000 or rising rapidly, AKI, hyperkalemia

— Need for intubation, paralysis, or active cooling

— Severe altered mental status (GCS ≤10) or aspiration

— Refractory disease requiring dantrolene/bromocriptine combination or ECT

— Mild disease, stable vitals, CK <5,000, tolerating PO meds

— Continuous telemetry, q1–2h vitals, serial CK q6h

— Critical care — early, before decompensation

— Psychiatry — medication history, future antipsychotic plan, capacity assessment, ECT planning

— Neurology — atypical features, catatonia overlap, parkinsonism-hyperpyrexia

— Toxicology / Poison Control — mixed ingestions, refractory cases

— Nephrology — AKI requiring RRT

— Pharmacy — medication reconciliation, dantrolene/bromocriptine dosing, drug interactions

— If receiving facility lacks ICU, ECT, or dialysis capability → transfer early once stabilized

— During transport: continue IVF, cooling, monitoring; communicate the offending drug clearly

— Discuss with surrogate if patient incapacitated; NMS itself is reversible, so default is aggressive care unless prior directive specifies otherwise

ICU admission criteria (any one):

Step-down/monitored bed:

Consultations:

Transfer considerations:

Code status / goals of care:

CCS pearl: On a CCS case, key high-value orders are ICU transfer, dantrolene, IVF bolus, foley, telemetry, psych consult, and update medication-allergy list — clustering these early scores well and reflects realistic ED-to-ICU handoff.

Board pearl: Any NMS patient requiring paralysis or intubation for hyperthermia control belongs in the ICU regardless of other parameters — the airway/sedation needs alone meet criteria.

Key Differentials — Same-Category (Hyperthermia + Altered Mental Status) Causes

— Triggers: SSRIs, SNRIs, MAOIs, tramadol, linezolid, methylene blue, triptans, MDMA, dextromethorphan, ondansetron + serotonergic combo

— Hyperreflexia, clonus (especially lower extremity), mydriasis, tremor, GI hyperactivity (diarrhea, hyperactive bowel sounds), shivering

— Onset rapid (<24 h after drug initiation/dose change)

— Treatment: stop agent, benzodiazepines, cyproheptadine if severe; avoid dantrolene as first-line (used only if hyperthermia severe), avoid bromocriptine (worsens)

— Trigger: volatile anesthetics (halothane, sevoflurane, isoflurane) + succinylcholine, intraoperatively

— Masseter spasm, rising ETCO₂, mixed acidosis, rigidity, hyperthermia

— Autosomal dominant ryanodine receptor mutation

— Treatment: dantrolene IV 2.5 mg/kg STAT, stop trigger, 100% O₂, cool

— Hot, dry, red skin, mydriasis, urinary retention, ileus, delirium ("mad as a hatter, dry as a bone")

— No rigidity, no diaphoresis

— Treatment: supportive; physostigmine in select cases

— Diaphoresis, mydriasis, agitation, hypertension, tachycardia, seizures

— Rigidity uncommon

— Treatment: benzodiazepines first-line; avoid pure beta-blockade (unopposed alpha)

— Antecedent psychiatric prodrome, no antipsychotic exposure necessary

— Treatment: benzodiazepines + ECT; antipsychotics may worsen

— NMS: dopamine block + rigidity + hyporeflexia, days timeline

— Serotonin: serotonin excess + clonus/hyperreflexia, hours timeline

— MH: volatile anesthetic + intraoperative onset

— Anticholinergic: dry skin, no rigidity

Serotonin syndrome:

Malignant hyperthermia:

Anticholinergic toxicity:

Sympathomimetic toxicity (cocaine, methamphetamine, MDMA, bath salts):

Lethal catatonia:

Key distinction (one-liner each):

Key Differentials — Other-Category Causes

— Fever, altered mental status, tachycardia, hypotension

— Lacks lead-pipe rigidity and marked CK elevation

— Must be co-considered and empirically treated until cultures back — NMS and sepsis can coexist (aspiration pneumonia in NMS)

— Headache, neck stiffness (meningismus, not generalized rigidity), photophobia, focal deficits, seizures

— LP shows pleocytosis; CSF in NMS is normal

— Hyperthermia, tachyarrhythmia (AF), agitation, tremor not rigidity, GI symptoms, exophthalmos, goiter

— TSH suppressed, free T4/T3 elevated

— Treatment: beta-blockers, PTU/methimazole, iodine, steroids

— Environmental exposure or exertion, anhidrosis in classic form, no drug trigger

— Same supportive cooling principles

— Episodic hypertension, headache, palpitations, diaphoresis; rigidity uncommon

— Altered mental status without obvious motor activity; EEG diagnostic

— Focal deficits, sudden onset; CT/MRI needed

— Alcohol/benzodiazepine withdrawal: tremor, autonomic hyperactivity, seizures, hallucinations — no lead-pipe rigidity; benzo-responsive

— Baclofen withdrawal (intrathecal pump failure): can mimic NMS with rigidity, fever, AMS — clue is intrathecal pump, treat by restarting baclofen and supportive care

— Trismus, opisthotonus, wound history, normal mentation early

Sepsis / septic encephalopathy:

CNS infection (meningitis, encephalitis):

Thyroid storm:

Heat stroke:

Pheochromocytoma crisis:

Nonconvulsive status epilepticus:

Intracranial catastrophe (hemorrhage, basilar stroke, hypothalamic injury):

Withdrawal syndromes:

Tetanus:

Board pearl: A patient with an intrathecal baclofen pump presenting with fever, rigidity, and altered mental status has baclofen withdrawal, not NMS — interrogate the pump and restart baclofen.

Key distinction: Always run cultures + empiric antibiotics in parallel with NMS workup; missing concurrent sepsis is a classic Step 3 cognitive-error stem.

Secondary Prevention and Long-Term Antipsychotic Plan

— Symptoms typically resolve over 7–14 days after stopping the offending agent

— Long-acting depot injections can prolong NMS for 2–4 weeks — anticipate slower recovery

— Wait at least 2 weeks (ideally 4–6 weeks) before reintroducing any antipsychotic

— Discuss risk vs. benefit with patient and family; obtain documented informed consent

— Choose lower-potency or lower D2-affinity agent: quetiapine, clozapine, olanzapine preferred over haloperidol/fluphenazine

— Use low starting dose, slow titration, monotherapy if possible

— Ensure adequate hydration, avoid restraints/IM injections, avoid concomitant lithium (lithium increases NMS risk)

— Counsel patient/family on early warning signs (fever, stiffness, confusion) and to seek ED immediately

— Never abruptly stop dopaminergic therapy; coordinate perioperative management with neurology

— Use rotigotine patch if NPO/cannot take PO levodopa

— Add the offending drug and drug class to the allergy/adverse reaction list in the EHR

— Notify outpatient pharmacy and PCP at discharge

— Provide patient with a written list of drugs to avoid (haloperidol, prochlorperazine, metoclopramide, promethazine, droperidol)

— Continue bromocriptine taper over 1–2 weeks

— Continue dantrolene taper over 7–10 days

— DVT prophylaxis until fully mobile

Recovery timeline:

Re-challenge principles (after full clinical recovery):

For Parkinson disease patients:

Medication reconciliation:

Discharge medications:

Step 3 management: Document a clear "do not re-administer" list with drug class (not just the single agent) on the discharge summary, and communicate explicitly to the receiving facility or outpatient psychiatrist — transitions-of-care failures are the most common cause of recurrence.

Board pearl: Clozapine has the lowest D2 affinity and lowest NMS recurrence rate; preferred for patients who relapse with treatment-resistant psychosis post-NMS, with ANC monitoring per REMS.

Follow-Up, Monitoring, and Counseling

— Daily CBC, CMP, CK, LFTs until trending normal

— Continuous telemetry until autonomic stability >24 h

— Strict I/O; goal UO >0.5–1 mL/kg/h

— Daily neuro and rigidity assessment

— Aspiration precautions, swallow evaluation by SLP before reintroducing PO

— Early mobilization, PT/OT consult

— Afebrile >48 h, normal mental status, CK trending down (<1,000) and AKI resolved

— Stable on oral medications (bromocriptine taper) with reliable PO intake

— Clear outpatient psychiatric and PCP follow-up arranged

— Caregiver/family education completed

— PCP within 1 week of discharge — vitals, exam, medication reconciliation

— Psychiatry within 1–2 weeks — discuss future antipsychotic strategy, mood stabilization

— Neurology at 4–6 weeks if Parkinson-hyperpyrexia or persistent parkinsonism

— Labs (BMP, CK, LFTs) at 1 and 4 weeks

— Educate patient and family on warning signs: fever, stiffness, confusion, sweating

— Carry a medication alert card listing the offending drug class

— Alcohol moderation; avoid dehydration, extreme heat

— Counsel on adherence to mental health treatment plan to prevent relapse

— PT for deconditioning, gait, rigidity-related stiffness

— Cognitive assessment at 4–6 weeks if persistent deficits — most resolve fully

Inpatient monitoring during recovery:

Discharge criteria:

Outpatient follow-up cadence:

Counseling points:

Rehab:

CCS pearl: Order swallow evaluation before PO meds; reintroducing dopaminergic or psychiatric meds via an unsafe swallow leads to aspiration, which is the most common readmission cause within 30 days of NMS.

Step 3 management: Schedule psychiatry follow-up within 1–2 weeks before discharge — failure to bridge psychiatric care in a patient whose antipsychotic was stopped risks decompensation, self-harm, and ED bouncebacks, a frequent transitions-of-care test point.

Ethical, Legal, and Patient Safety Considerations

— During acute NMS, patient typically lacks decision-making capacity due to altered mental status — obtain consent from surrogate decision-maker per state hierarchy (spouse, adult child, etc.)

— For ECT in refractory cases: requires specific informed consent, often court oversight if surrogate or patient is unable; emergency ECT can be performed under emergency exception in life-threatening cases with documented two-physician concurrence (state-dependent)

— Re-challenge with antipsychotics after recovery requires explicit, documented risk-benefit discussion while patient has restored capacity — including recurrence rate (~15–30%) and signs to watch

— NMS is a serious adverse drug reaction — report to FDA MedWatch; institutional pharmacy and patient safety committees may also require reports

— If NMS resulted from a prescribing or dispensing error → disclose to patient/family per institutional disclosure policy; engage risk management

— Physical or chemical restraints in agitated psychiatric patients are a risk factor for NMS (dehydration, IM antipsychotics); follow least-restrictive-means policy, document indication, time-limit orders, monitor q15 min

— Avoid IM haloperidol boluses in agitated patients who are already restrained, dehydrated, or hyperthermic

— The single most dangerous moment is handoff between psychiatric facility ↔ medical floor ↔ outpatient — ensure the offending drug is flagged in the allergy list with the class, communicated verbally at handoff, and reflected on discharge medication reconciliation

— Coordinate with outpatient pharmacy to prevent inadvertent re-dispensing

— Black patients are disproportionately prescribed high-potency typicals historically — be aware of prescribing patterns contributing to NMS risk

Informed consent and capacity:

Mandatory reporting and disclosure:

Restraint use:

Transitions of care:

Health equity:

Step 3 management: A diagnosis of NMS triggers four mandatory actions before discharge — (1) EHR adverse-reaction entry with drug class, (2) MedWatch report, (3) written patient handout listing drugs to avoid, (4) direct communication with outpatient prescriber. Missing any of these is a tested patient-safety failure.

High-Yield Associations and Rapid-Fire Clinical Facts

— Mild → stop drug + IVF + cooling + benzodiazepines

— Moderate → add dantrolene ± bromocriptine

— Severe/refractory → ECT, ICU paralysis

Classic tetrad: fever, rigidity, autonomic instability, altered mental status

Most common offenders: haloperidol, fluphenazine, metoclopramide, prochlorperazine, promethazine

Onset: typically within 2 weeks of starting or dose-escalating a D2 antagonist; 90% within 10 days

Risk factors: young male, dehydration, agitation, restraints, depot injection, prior NMS, catatonia, lithium co-use, iron deficiency

Lab triad: ↑CK, leukocytosis, ↓serum iron

Mortality: 5–20% untreated; <5% with prompt recognition

Recurrence with re-challenge: 15–30%

Wait at least 2 weeks before re-challenge; prefer low-D2 atypicals (quetiapine, clozapine)

Antipyretics ineffective — physical cooling only

Avoid anticholinergics — worsen hyperthermia

Treatments tiered by severity:

Dantrolene: ryanodine receptor blocker; hepatotoxic

Bromocriptine: D2 agonist; continue 10–14 days, taper to avoid rebound

Parkinson-hyperpyrexia syndrome = NMS-equivalent from levodopa withdrawal → restart levodopa

Baclofen pump withdrawal mimics NMS → restart baclofen

Lithium + antipsychotic combination increases NMS risk

Clozapine has the lowest NMS recurrence risk

ECT is safe and effective in pregnancy and refractory NMS

PE is a leading cause of NMS-associated death — start chemoprophylaxis early

Serum CK level correlates with severity and AKI risk

Anesthesia in NMS patient: avoid succinylcholine if hyperkalemic, use rocuronium

In CCS: always order medication discontinuation, IVF, cooling, telemetry, ICU consult, psych consult, MedWatch documentation

Board pearl: Three drugs commonly missed as NMS triggers on the exam: metoclopramide, prochlorperazine, promethazine — all are D2 antagonists prescribed as antiemetics, not antipsychotics.

Board Question Stem Patterns

— "48 h after haloperidol initiation for acute psychosis, a 32-year-old man develops T 40.1°C, lead-pipe rigidity, BP 170/100 fluctuating to 90/60, CK 8,500, WBC 18 k…"

— Answer: stop haloperidol, IVF, cooling, lorazepam, admit to ICU, add dantrolene if severe

— Postoperative or chemotherapy patient receiving metoclopramide or prochlorperazine develops fever, rigidity, AMS — answer is NMS; the offender is the antiemetic

— PD patient admitted for surgery, levodopa held overnight, develops fever and rigidity → parkinsonism-hyperpyrexia; restart levodopa via NG

— Stem features clonus, hyperreflexia, diarrhea, recent SSRI + tramadol → serotonin syndrome → cyproheptadine + benzos, not dantrolene first

— Patient already on dantrolene + bromocriptine 72 h without improvement → next best step is ECT

— After NMS recovery, schizophrenic patient needs antipsychotic restart — best choice is quetiapine or clozapine after at least 2 weeks, low dose, slow titration

— Heme-positive urine without RBCs + CK 20,000 + AKI + recent risperidone = NMS with rhabdomyolysis → IVF goal UO 1–3 mL/kg/h

— Peripartum psychosis treated with haloperidol, develops NMS unresponsive to dantrolene → ECT is correct answer

— Spasticity patient with intrathecal baclofen pump develops NMS-like syndrome → baclofen withdrawal, restart intrathecal baclofen

— NMS resolved, ready for discharge — best next step is document adverse drug reaction in EHR, notify outpatient prescriber, MedWatch report

Pattern 1 — Classic psychiatric inpatient:

Pattern 2 — Antiemetic trap:

Pattern 3 — Parkinson disease NPO:

Pattern 4 — Serotonin vs. NMS distinguishing:

Pattern 5 — Refractory NMS:

Pattern 6 — Re-challenge planning:

Pattern 7 — Lab pattern:

Pattern 8 — Pregnancy refractory:

Pattern 9 — Baclofen pump:

Pattern 10 — Patient safety:

Step 3 management: When two answers look correct (e.g., "give dantrolene" vs. "stop antipsychotic"), the always-first answer is stop the offending drug — board logic favors the cause-removing step over symptomatic therapy.

One-Line Recap

Neuroleptic malignant syndrome is a life-threatening idiosyncratic reaction to dopamine D2 antagonism — recognized by fever, lead-pipe rigidity, autonomic instability, and altered mental status — managed by immediate discontinuation of the offending drug, aggressive IV fluids and physical cooling, benzodiazepines for mild–moderate disease, dantrolene plus bromocriptine for severe cases, and ECT for refractory disease, with careful re-challenge planning using low-D2 atypicals after at least 2 weeks.

High-yield recap bullets:

Tetrad + trigger: fever, rigidity, autonomic instability, AMS occurring within 2 weeks of a D2 antagonist (haloperidol, fluphenazine, metoclopramide, prochlorperazine, promethazine) — or after abrupt levodopa withdrawal in Parkinson disease (parkinsonism-hyperpyrexia syndrome).

Lab pattern: ↑CK (often >1,000–10,000), leukocytosis, ↓serum iron, myoglobinuric AKI, metabolic acidosis — but NMS remains a clinical diagnosis; rule out sepsis, meningitis, serotonin syndrome, malignant hyperthermia, and thyroid storm in parallel.

Management ladder: (1) stop drug + IVF + physical cooling + benzodiazepines for all; (2) add dantrolene (ryanodine blocker) and bromocriptine (D2 agonist) for moderate–severe; (3) ECT for refractory disease or peripartum patients — antipyretics don't work and anticholinergics worsen hyperthermia.

Safety + transitions: document adverse reaction with drug class in EHR, file MedWatch, give patient written avoid-list, schedule psychiatry follow-up within 1–2 weeks, and re-challenge only after ≥2 weeks using clozapine or quetiapine — recurrence rate 15–30% if rushed.

Board pearl: When in doubt on the exam, the first action in NMS is always discontinue the dopamine antagonist — every subsequent therapy is supportive.